Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study.
Methotrexate
Polyglutamates
Sarcoidosis
Treatment response
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
11
09
2023
accepted:
05
11
2023
medline:
27
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Methotrexate (MTX), a folate antagonist, is often used as second-line treatment in patients with sarcoidosis. Effectiveness of MTX has large inter-patient variability and at present therapeutic drug monitoring (TDM) of MTX is not possible. Upon administration, MTX is actively transported into cells and metabolized to its active forms by adding glutamate residues forming MTXPG We retrospectively included patients with sarcoidosis that had started on MTX therapy and from whom blood samples and FDG-PET/CT were available 3 and 6-12 months after MTX initiation, respectively. FDG-uptake was measured by SUVmax in the heart, lungs and thoracic lymph nodes. Changes in SUVmax was used to determine anti-inflammatory response after 6-12 months of MTX therapy. MTXPG We included 42 sarcoidosis patients treated with MTX (15 mg/week); 31 with cardiac sarcoidosis and 11 with pulmonary sarcoidosis. In MTXPG These results suggest a relation between MTXPG
Identifiants
pubmed: 37973683
doi: 10.1007/s00408-023-00656-0
pii: 10.1007/s00408-023-00656-0
doi:
Substances chimiques
methotrexate polyglutamate
82334-40-5
Methotrexate
YL5FZ2Y5U1
Fluorodeoxyglucose F18
0Z5B2CJX4D
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-624Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Patterson KC, Chen ES (2018) The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. https://doi.org/10.1016/j.chest.2017.11.030
doi: 10.1016/j.chest.2017.11.030
pubmed: 29224832
Valeyre D, Prasse A, Nunes H et al (2014) Sarcoidosis. The Lancet 383:1155–1167. https://doi.org/10.1016/S0140-6736(13)60680-7
doi: 10.1016/S0140-6736(13)60680-7
Baughman RP, Valeyre D, Korsten P et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 58:2004079. https://doi.org/10.1183/13993003.04079-2020
doi: 10.1183/13993003.04079-2020
pubmed: 34140301
Kahlmann V, Janssen Bonás M, Moor CC et al (2020) Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med 20:271. https://doi.org/10.1186/s12890-020-01290-9
doi: 10.1186/s12890-020-01290-9
pubmed: 33076885
pmcid: 7574228
Vis R, Mathijssen H, Keijsers RGM et al (2023) Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis. J Nucl Cardiol. https://doi.org/10.1007/s12350-022-03171-6
doi: 10.1007/s12350-022-03171-6
pubmed: 36640249
Castaldo P, Magi S, Nasti AA et al (2011) Clinical pharmacogenetics of methotrexate. Curr Drug Metab 12:278–286. https://doi.org/10.2174/138920011795101840
doi: 10.2174/138920011795101840
pubmed: 21470106
Krajinovic M, Moghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819–834. https://doi.org/10.1517/14622416.5.7.819
doi: 10.1517/14622416.5.7.819
pubmed: 15469405
Rots MG, Pieters R, Peters GJ et al (1999) Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93:1677–1683
doi: 10.1182/blood.V93.5.1677
pubmed: 10029597
Humbert M, Kovacs G, Hoeper MM et al (2023) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61:2200879. https://doi.org/10.1183/13993003.00879-2022
doi: 10.1183/13993003.00879-2022
pubmed: 36028254
Vorselaars ADM, Wuyts WA, Vorselaars VMM et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144:805–812. https://doi.org/10.1378/chest.12-1728
doi: 10.1378/chest.12-1728
pubmed: 23538719
Tishler M, Caspi D, Graff E et al (1989) Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 28:422–423. https://doi.org/10.1093/rheumatology/28.5.422
doi: 10.1093/rheumatology/28.5.422
pubmed: 2790404
Dalrymple JM, Stamp LK, O’Donnell JL et al (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299–3308. https://doi.org/10.1002/art.24034
doi: 10.1002/art.24034
pubmed: 18975321
de Rotte MCFJ, Pluijm SMF, de Jong PHP et al (2018) Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS ONE. https://doi.org/10.1371/journal.pone.0208534
doi: 10.1371/journal.pone.0208534
pubmed: 30532219
pmcid: 6287811
Halilova KI, Brown EE, Morgan SL et al (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012:1–7. https://doi.org/10.1155/2012/978396
doi: 10.1155/2012/978396
Bulatović Ćalasan M, den Boer E, de Rotte MCFJ et al (2015) Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2013-203723
doi: 10.1136/annrheumdis-2013-203723
De Rotte MCFJ, Den Boer E, De Jong PHP et al (2015) Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 74:408–414. https://doi.org/10.1136/annrheumdis-2013-203725
doi: 10.1136/annrheumdis-2013-203725
pubmed: 24297383
den Boer E, de Rotte MCJF, Pluijm SMF et al (2014) Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. https://doi.org/10.3899/jrheum.131290
doi: 10.3899/jrheum.131290
van de Meeberg MM, Seinen ML, Fidder HH et al (2022) Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn’s disease: a cross-sectional study. BMC Gastroenterol 22:365. https://doi.org/10.1186/s12876-022-02439-y
doi: 10.1186/s12876-022-02439-y
pubmed: 35907797
pmcid: 9338675
Schimmelpennink MC, Vorselaars ADM, Veltkamp M, Keijsers RGM (2019) Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis. EJNMMI Res. https://doi.org/10.1186/s13550-019-0505-x
doi: 10.1186/s13550-019-0505-x
pubmed: 31197630
pmcid: 6565791
Bakker AL, Grutters JC, Keijsers RG, Post MC (2017) Cardiac sarcoidosis: challenges in clinical practice. Curr Opin Pulm Med. https://doi.org/10.1097/MCP.0000000000000410
doi: 10.1097/MCP.0000000000000410
pubmed: 28661904
Adams H, Keijsers RG, Korenromp IHE, Grutters JC (2014) FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med. https://doi.org/10.1055/s-0034-1376866
doi: 10.1055/s-0034-1376866
pubmed: 25007087
Crouser ED, Maier LA, Wilson KC et al (2020) Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 201:e26–e51. https://doi.org/10.1164/rccm.202002-0251ST
doi: 10.1164/rccm.202002-0251ST
pubmed: 32293205
pmcid: 7159433
Takahashi C, Kaneko Y, Okano Y et al (2017) Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3:e000363. https://doi.org/10.1136/rmdopen-2016-000363
doi: 10.1136/rmdopen-2016-000363
pubmed: 28123781
pmcid: 5237762
den Boer E, Meesters RJW, van Zelst BD et al (2013) Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem 405:1673–1681. https://doi.org/10.1007/s00216-012-6581-7
doi: 10.1007/s00216-012-6581-7
Jh O, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 280:576–584. https://doi.org/10.1148/radiol.2016142043
doi: 10.1148/radiol.2016142043
Pinker K, Riedl C, Weber WA (2017) Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging 44:55–66. https://doi.org/10.1007/s00259-017-3687-3
doi: 10.1007/s00259-017-3687-3
pubmed: 28361188
pmcid: 5542859
Fischer M, Siva S, Cook GK et al (2017) Methotrexate polyglutamate monitoring in patients with Crohn’s disease. Clin Pharmacol Drug Dev 6:240–245. https://doi.org/10.1002/cpdd.279
doi: 10.1002/cpdd.279
pubmed: 27274011
Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145–154. https://doi.org/10.1038/s41584-020-0373-9
doi: 10.1038/s41584-020-0373-9
pubmed: 32066940
Stamp LK, O’Donnell JL, Chapman PT et al (2009) Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 60:2248–2256. https://doi.org/10.1002/art.24653
doi: 10.1002/art.24653
pubmed: 19644853
Hebing RCF, Bartelink IH, Gosselt H et al (2023) Methotrexate polyglutamates exposure—response modeling in a large cohort of rheumatoid arthritis patients starting methotrexate. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.2974
doi: 10.1002/cpt.2974
pubmed: 37313979
Zhao Z, Hua Z, Luo X et al (2022) Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother 150:113074. https://doi.org/10.1016/j.biopha.2022.113074
doi: 10.1016/j.biopha.2022.113074
pubmed: 35658215
Pan S, Stamp LK, Duffull SB et al (2014) Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. https://doi.org/10.1007/s40262-014-0179-5
doi: 10.1007/s40262-014-0179-5
pubmed: 25204405
Keijsers RGM, Grutters JC (2020) In which patients with sarcoidosis is FDG PET/CT indicated? J Clin Med. https://doi.org/10.3390/jcm9030890
doi: 10.3390/jcm9030890
pubmed: 32213991
pmcid: 7141490
Markatis E, Afthinos A, Antonakis E, Papanikolaou IC (2020) Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med 21:321. https://doi.org/10.31083/j.rcm.2020.03.102
doi: 10.31083/j.rcm.2020.03.102
pubmed: 33070538